The story of Viagra presents a nuanced case for stakeholders in the medicinal sector. While initially a tremendous success, producing billions, the patent lapse and the subsequent entry of cheaper competitors have considerably affected income. This poses questions about the ongoing viability of similar therapeutic developments and suggests that … Read More